PMDD Treatment Options: SSRIs, Hormonal Approaches and Tracking

The first-line treatments for premenstrual dysphoric disorder (PMDD) are SSRI antidepressants, taken either every day or only in the second half of the cycle, and, for people who want contraception, a drospirenone-containing birth control pill. Sertraline, extended-release paroxetine and fluoxetine are FDA-approved for PMDD, as is the oral contraceptive Yaz; the fluoxetine brand Sarafem has been discontinued, but generic fluoxetine tablets carry the indication. Cognitive behavioral therapy (CBT) can help with mood symptoms, and medicines that switch off ovulation are kept for severe cases that have not responded.

Treatment starts with an accurate diagnosis. The DSM-5 criteria say symptoms should be confirmed by daily ratings over at least two symptomatic cycles, so tracking is the first practical step. PMDD is also linked to suicidal thoughts and attempts, which makes it worth taking seriously rather than writing off as "bad PMS."

What makes it PMDD rather than PMS

PMDD is a depressive disorder tied to the menstrual cycle. Under the DSM-5 criteria, in most cycles at least five symptoms appear in the final week before a period, start to improve within a few days after it begins, and become minimal or absent in the week after. At least one must be a core mood symptom:

• Marked mood swings or sudden sadness, or increased sensitivity to rejection
• Marked irritability, anger or more conflict with others
• Marked depressed mood, hopelessness or self-critical thoughts
• Marked anxiety or tension, feeling keyed up or on edge

The rest can come from a second list: less interest in usual activities, trouble concentrating, fatigue, appetite changes or cravings, sleeping too much or too little, feeling overwhelmed, and physical symptoms such as breast tenderness, bloating or joint pain. The symptoms must cause real distress or interfere with work, school, social life or relationships, and must not simply be a worsening of another condition such as major depression or panic disorder. The DSM-5 reports a 12-month prevalence of PMDD of about 1.8% to 5.8% among menstruating women in the United States.

Step one: track for two cycles

Because memory is unreliable for cyclical symptoms, the DSM-5 requires prospective daily ratings across at least two symptomatic cycles to confirm the diagnosis, though a clinician can make a provisional diagnosis while you track. The Yaz PMDD trials, for example, enrolled women whose diagnosis was confirmed by prospective daily ratings.

How to track in practice:

1. Use a daily form or app that rates each symptom on a simple severity scale. Validated tools such as the Daily Record of Severity of Problems exist; ask your clinician which they prefer.
2. Rate every day, not just bad days, and mark the first day of each period.
3. Note sleep, alcohol, unusual stress and any medications, including hormonal contraception.
4. Bring the charts to the appointment. A clear symptom-free stretch after the period supports PMDD; symptoms that never fully lift point toward another condition or premenstrual worsening.

If the charts show symptoms most days of the month that only get worse before your period, the more likely explanation is premenstrual worsening of an ongoing condition such as depression or an anxiety disorder. That is still treatable, and it is useful to know: the main treatment then targets the ongoing condition, sometimes with an adjustment before each period, rather than PMDD-specific options alone. The guide to depression treatment options covers that path.

Tracking is not a reason to delay help if you are in serious distress. Treatment can start on a provisional diagnosis, and tracking continues alongside it.

PMDD treatments compared

SSRIs: daily or only before your period

SSRIs are the most studied PMDD treatment. Sertraline, escitalopram, paroxetine and fluoxetine have all shown efficacy whether taken continuously or only in the luteal phase. Their effect in PMDD appears to be faster and to come at lower doses than in depression or anxiety, which suggests a different mechanism. That is one reason luteal-phase dosing, which is not used for depression, can work for PMDD.

How to choose between the two schedules is a decision to make with your prescriber. Luteal-phase dosing means less total medication and fewer days of side effects, and it suits people with regular cycles and a clear symptom-free stretch. Daily dosing is simpler with irregular cycles, avoids the stop-start pattern, and makes sense when there are some symptoms all month or another condition such as depression or anxiety. The labels describe both options for sertraline, Paxil CR and fluoxetine tablets.

Points to raise with the prescriber:

• The fluoxetine PMDD trials excluded women taking oral contraceptives, so combining an SSRI with the pill has less direct evidence.
• Prescribers screen for bipolar disorder before starting an antidepressant, because antidepressants can trigger mania in people at risk.
• Antidepressant labels carry a boxed warning about suicidal thoughts and behaviors in children, adolescents and young adults, so younger patients need closer follow-up.
• If side effects such as sexual or sleep changes bother you, tell the prescriber rather than stopping on your own.

For how SSRIs differ from each other, see fluoxetine vs sertraline and SSRI vs SNRI vs bupropion.

Hormonal approaches

Drospirenone-containing birth control pills

A combined pill containing drospirenone and ethinyl estradiol (Yaz) is FDA-approved to treat PMDD symptoms in women who choose an oral contraceptive for birth control. The label notes that its PMDD effectiveness has not been evaluated beyond three cycles and that it has not been evaluated for ordinary PMS. Like other combined pills, it carries a boxed warning that cigarette smoking increases the risk of serious cardiovascular events, and women over 35 who smoke should not use it. ACOG's 2023 guideline on premenstrual disorders reviews hormonal and nonhormonal medicines, therapy, lifestyle measures and surgery, and notes that many patients benefit from combining approaches.

Suppressing ovulation for severe, resistant PMDD

When SSRIs and a drospirenone pill have not worked, specialists may consider a GnRH agonist such as leuprolide, which suppresses ovulation and with it the hormonal changes that trigger symptoms. These drugs are not FDA-approved for PMDD: the Lupron Depot 3.75 mg label covers endometriosis and anemia from fibroids. They create a menopause-like state with hot flashes and loss of bone density, some of which may not reverse, so they are typically combined with "add-back" estrogen and progestin; in some people the progestin can bring symptoms back. Surgical removal of the ovaries and uterus has been used as a last resort for refractory PMDD and requires hormone replacement afterward. These steps belong with a gynecologist experienced in PMDD, ideally working with a psychiatrist.

Therapy, lifestyle and supplements

Several therapies have been studied for PMS and PMDD, and the balance of evidence favors CBT, though the quality of the trials is low. CBT for PMDD usually focuses on recognizing the premenstrual window, planning around it, managing irritability and conflict, and challenging the harsh thoughts that peak in that week. It can be combined with medication. The site's page on psychotherapy describes the practice's therapy approach, and CBT vs psychodynamic therapy compares approaches.

Calcium has some trial evidence for PMS symptoms, with a small overall effect, and vitamin B6 is included in some UK guidance despite low-quality evidence. Exercise appears in guidance as well. These are reasonable additions to discuss, but the evidence does not support them as replacements for SSRIs or hormonal treatment in PMDD. Benzodiazepines have only sparse, outdated evidence for premenstrual symptoms. If you are considering supplements, ask your prescriber about interactions and doses.

Common mistakes that delay relief

• Relying on memory instead of daily ratings. Recalled symptoms tend to blur the pattern, and a chart often changes the diagnosis or the plan.
• Stopping a luteal-phase SSRI after one cycle. Give a treatment a fair trial over several cycles while you keep tracking, and review the charts with the prescriber.
• Assuming any birth control pill will help. Only one formulation has an FDA indication for PMDD, and some people notice their mood worsens on hormonal contraception.
• Treating PMDD while missing a condition that is present all month, such as depression, anxiety or ADHD, which needs its own treatment.
• Waiting through severe premenstrual hopelessness or suicidal thoughts because "it will pass in a few days." Those symptoms need prompt attention every time.
• Adding several supplements at once, which makes it impossible to tell what helped and can create interactions.

Who treats PMDD

• A gynecologist or primary care clinician can confirm the cycle pattern, rule out other gynecologic and medical problems, prescribe a drospirenone pill, and often start an SSRI.
• A psychiatrist or psychiatric nurse practitioner is useful when mood symptoms are severe, when depression, anxiety, ADHD or bipolar disorder may be present, when there are suicidal thoughts, or when the first SSRI has not worked. A reproductive psychiatrist specializes in these questions; see what a reproductive psychiatrist does.
• A therapist provides CBT and coping strategies for the premenstrual window.

When more than one clinician is involved, ask them to coordinate, especially if one is adjusting hormones and another an antidepressant. Coordinating primary care and psychiatry covers how to make that work. ACOG's guideline applies to adolescents as well as adults, with some exceptions noted in the full text, so teens can be assessed and treated too.

Questions to bring:

1. Do my tracking charts fit PMDD, or premenstrual worsening of something else?
2. Should I try an SSRI daily or only in the luteal phase, given my cycle regularity?
3. Is a drospirenone pill an option for me, given my age, smoking status and other health history?
4. What is the next step if the first treatment does not help?
5. How will we handle it if my mood symptoms get worse?

PMDD across life stages

PMDD can change over time. Symptoms may shift after childbirth or when starting or stopping hormonal contraception, and the years before menopause can bring more erratic hormone swings and mood changes. If your symptoms are changing in your forties, see perimenopause depression: HRT or antidepressants. The site's article on ADHD and the menstrual cycle explains how hormones can affect ADHD symptoms, which sometimes overlap with premenstrual changes.

If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room. If suicidal thoughts come back each cycle, a written plan made in a calm week helps; see safety planning for suicidal thoughts.

How the practice can help

Dr. Lewis's team includes psychiatrists, psychiatric nurse practitioners and psychotherapists, and care can combine psychiatric evaluation and medication management, psychotherapy including CBT and DBT, lab testing, coaching, and nutrition and lifestyle psychiatry. The practice's medication management page describes how prescribing works, and individual care starts with the Patient Interest Form. If you need care that is in network with your plan, ask the team on the discovery call about options. For other conditions and starting points, see the Choosing Psychiatric Care guide.

Frequently asked questions

Do I have to wait two months of tracking before getting treatment?

No. Confirming PMDD formally requires two cycles of daily ratings, but a clinician can make a provisional diagnosis and start treatment while you keep tracking.

Can I take an SSRI only the week or two before my period?

For PMDD, yes, luteal-phase dosing is an approved approach for several SSRIs and has shown efficacy in trials. Whether it suits you depends on how regular your cycles are and whether you have symptoms at other times. Decide the schedule with your prescriber.

Will any birth control pill help PMDD?

The pill with an FDA indication for PMDD contains drospirenone and ethinyl estradiol. Other pills have less evidence, and some people find hormonal contraception worsens mood. Discuss options with your gynecologist or prescriber.

Is PMDD a hormone imbalance I can test for?

There is no blood test that diagnoses PMDD, and hormone testing has not been shown to be useful for diagnosis. Daily symptom tracking across cycles is the standard.

Can I use an SSRI and the pill together?

Many people do, but the fluoxetine PMDD trials excluded people taking oral contraceptives, so there is less direct evidence for the combination. Your prescriber can weigh the options.

What if nothing has worked?

Confirm the diagnosis with tracking, check for another condition that worsens premenstrually, and consider a different SSRI or schedule. For severe, resistant PMDD, a gynecologist may discuss ovulation suppression with add-back hormones.

Sources

1. Management of Premenstrual Dysphoric Disorder: A Scoping Review. International Journal of Women's Health (Carlini et al.), 2022. pmc.ncbi.nlm.nih.gov
2. Management of Premenstrual Disorders: ACOG Clinical Practice Guideline No. 7. Obstetrics & Gynecology (ACOG), 2023. pubmed.ncbi.nlm.nih.gov
3. Zoloft (sertraline) prescribing information. DailyMed / U.S. FDA label, 2023. dailymed.nlm.nih.gov
4. Paxil CR (paroxetine extended-release) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
5. Fluoxetine tablets prescribing information. DailyMed / U.S. FDA label (Torrent), 2024. dailymed.nlm.nih.gov
6. Yaz (drospirenone and ethinyl estradiol) prescribing information. DailyMed / U.S. FDA label, 2023. dailymed.nlm.nih.gov
7. Lupron Depot 3.75 mg (leuprolide acetate) prescribing information. DailyMed / U.S. FDA label, 2025. dailymed.nlm.nih.gov
8. Paxil (paroxetine) prescribing information. DailyMed / U.S. FDA label, 2026. dailymed.nlm.nih.gov
9. Lexapro (escitalopram) prescribing information. DailyMed / U.S. FDA label, 2023. dailymed.nlm.nih.gov
10. Drugs@FDA: SARAFEM (NDA 021860). U.S. Food and Drug Administration, 2026. accessdata.fda.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.